Bifunctional Peptidoglycan/Chitin Hydrolase for Hyphae Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Fungal and bacterial pathogens, such as Candida albicans, cause significant morbidity and mortality due to hyphae formation, which is a critical step in biofilm formation, leading to increased resistance to antifungal drugs and host defenses, and existing treatments like azoles face rising resistance issues.
Innovation Solution
A bifunctional peptidoglycan/chitin hydrolase, particularly Msp1 from Lactobacillus strains, inhibits hyphae formation by cleaving chitin and peptidoglycan in the pathogen cell wall, optionally enhanced by an acidic environment created by lactic acid, thereby preventing biofilm formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antifungal compounds such as azoles are used to treat fungal infections, then fungal infections can be treated, but resistance to these antifungals is rising and worrisome
Solution Approach 1:
The patent extracts and targets the specific virulence factor (hyphae formation) rather than killing the entire pathogen. By using peptidoglycan/chitin hydrolases to specifically degrade the cell wall components required for hyphae formation, the invention bypasses traditional antifungal resistance mechanisms while maintaining effective treatment of fungal infections
Solution Approach 2:
The invention changes the treatment approach from inhibiting fungal growth broadly (traditional antifungals) to specifically degrading cell wall structural components (peptidoglycan and chitin). This parameter change in the mechanism of action creates a new therapeutic pathway that is not subject to existing antifungal resistance
2Object-affected harmful factors
If hyphae formation is promoted for tissue penetration, then pathogenicity increases, but this same process creates biofilm formation that increases resistance to antifungals and host defenses
Solution Approach 1:
The patent applies preliminary anti-action by preventing hyphae formation before biofilm development occurs. By using peptidoglycan/chitin hydrolases to degrade cell wall components during the early stages of fungal growth, the invention prevents the transition to the hyphal form that would otherwise lead to biofilm formation and subsequent drug resistance
Solution Approach 2:
The invention converts the structural components of the fungal cell wall (peptidoglycan and chitin) that normally provide strength and protection into targets for therapeutic degradation. By harnessing these same structural elements as vulnerability points, the patent turns the pathogen's defensive features into weaknesses that can be exploited therapeutically
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bifunctional peptidoglycan/chitin hydrolase effectively reduces and prevents hyphae formation in pathogens, enhancing the efficacy of antifungal treatments and potentially inhibiting biofilm development, thus addressing drug resistance and improving treatment outcomes.
Implementation Method 1
A bifunctional peptidoglycan/chitin hydrolase, particularly Msp1 from Lactobacillus strains, inhibits hyphae formation by cleaving chitin and peptidoglycan in the pathogen cell wall
Implementation Method 2
optionally enhanced by an acidic environment created by lactic acid
Data Source
AI summary
The present invention generally relates to the use of a bifunctional peptidoglycan/chitin hydrolase to reduce and/or prevent hyphae formation in a pathogen, and/or to reduce or prevent biofilm formation. The present invention further relates to a bifunctional peptidoglycan/chitin hydrolase for use in the treatment and/or prevention of pathogenic infections, in particular yeast or bacterial infections. In another aspect, the present invention provides the use of a bifunctional peptidoglycan/chitin hydrolase as a anti-pathogenic agent in non-medical applications; in particular in the personal hygiene industry, food industry, cleaning industry, pharma industry, or biocontrol and crop protection industry.